UK: Pfizer to acquire Andera-backed ReViral for US$525m

American multinational pharmaceutical company, Pfizer, is to acquire Andera-backed ReViral for up to US$525m. ReViral, is a UK-based privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). RSV is a respiratory pathogen, which can lead to severe and life-threatening lower respiratory tract infections (LRTIs)…

You must be a HMI Subscriber to view this content.

Subscribe Now »